Hence, it is possible to restore TAM recognition and phagocytosis of tumor cells and to activate anti-neoplastic immune responses by interfering with the SIRPα-CD47 axis (e.g., by using antibodies to SIRPα and CD47) (126). This evidence concerns the gene SIRPA and neoplasm.